The Food and Drug Administration has granted accelerated approval to elranatamab-bcmm, marketed by Pfizer as Elrexfio, for adults with relapsed or refractory multiple myeloma who have already received at least four prior lines of therapy. In the 97-patient population used for the primary efficacy analysis, the drug produced a 57.7% objective response rate, according to the FDA’s Aug. 14 approval notice.

The approval adds another bispecific antibody to a rapidly changing treatment landscape for patients whose disease has persisted despite proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibodies. Elrexfio links the B-cell maturation antigen, or BCMA, on myeloma cells to CD3 on T cells, bringing the immune cell into close proximity with the cancer cell and activating a targeted immune response.

The approval rests on a single-arm Phase 2 trial

FDA evaluated Elrexfio in MagnetisMM-3, an open-label, multicenter Phase 2 study. The registered clinical-trial protocol enrolled patients with relapsed or refractory multiple myeloma whose disease was refractory to at least one proteasome inhibitor, one immunomodulatory medicine and one anti-CD38 monoclonal antibody. The trial did not randomly assign patients to a control arm, so the accelerated approval is based on the magnitude and durability of responses rather than a direct comparison with another therapy.

Among 97 patients in the efficacy population who had not previously received BCMA-directed treatment and received the recommended dosing regimen, the objective response rate was 57.7%, with a 95% confidence interval of 47.3% to 67.7%. Median duration of response had not been reached at the data cutoff. FDA reported that 90.4% of responders remained in response at six months and 82.3% at nine months.

The agency’s Drug Trials Snapshot provides additional detail on the approval dataset: 187 patients participated in the supporting study, safety was assessed in 183 people treated at the recommended regimen, and the trial was conducted at 53 centers in 10 countries. The snapshot also underscores the advanced disease burden of the population selected for approval.

A ready-to-use bispecific offers a different treatment model

Elrexfio is given as a subcutaneous injection and does not require the individualized cell collection and manufacturing process used for CAR-T cell therapies. Pfizer’s approval announcement describes the medicine as an off-the-shelf, fixed-dose BCMA-directed therapy, with a dosing schedule that can move from weekly treatment to every other week after 24 weeks in patients who have achieved and maintained at least a partial response for two months.

The regimen begins with step-up doses intended to reduce the severity of cytokine release syndrome. Patients receive 12 mg on day 1, 32 mg on day 4 and the first full 76-mg treatment dose on day 8, followed by weekly dosing. Because the immune activation that makes bispecific antibodies effective can also produce serious toxicities, the initial treatment period requires structured monitoring.

Interest in the medicine predates the approval. A June 2023 Journal of Clinical Oncology abstract from MagnetisMM-3 reported activity across difficult high-risk subgroups and documented substantial grade 3 or 4 treatment-emergent adverse events. Those results helped frame the central clinical tradeoff now reflected in the label: meaningful activity in heavily treated disease paired with significant immune and neurologic risk.

Safety warnings are central to how the drug will be used

Elrexfio carries boxed warnings for cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome, or ICANS. FDA reported cytokine release syndrome in 58% of patients treated at the recommended dosage, neurologic toxicity in 59% and ICANS in 3.3%. The drug is therefore available only through a Risk Evaluation and Mitigation Strategy designed to ensure clinicians and treatment centers follow required precautions.

An Aug. 15 Oncology Nursing Society summary emphasizes the importance of the step-up schedule and monitoring for fever, hypotension, hypoxia, altered mental status and other signs of immune-mediated toxicity. For patients already weakened by multiple lines of therapy, infection and blood-count abnormalities also remain important concerns.

The safety burden means the medicine is not simply another outpatient injection. Treatment programs must be prepared to manage acute immune reactions, observe patients after step-up dosing and educate patients and caregivers about symptoms that require rapid medical attention. That infrastructure requirement will influence where and how quickly the therapy can be adopted.

Accelerated approval leaves a confirmatory obligation

The FDA used its accelerated-approval pathway, which allows earlier access to medicines for serious diseases based on evidence considered reasonably likely to predict clinical benefit. Continued approval for Elrexfio’s indication is contingent on verification of clinical benefit in confirmatory studies. Pfizer says it is pursuing a broader MagnetisMM development program that will test the drug in earlier treatment lines and in combinations with other therapies.

The distinction matters because the current approval does not establish that Elrexfio improves overall survival compared with another treatment. It establishes that a substantial proportion of heavily pretreated patients experienced tumor responses that, at the current follow-up, often persisted for months. Confirmatory trials will have to determine how those responses translate into longer-term outcomes and where the drug fits relative to other BCMA-directed therapies.

Multiple myeloma remains treatable but generally incurable, and patients commonly cycle through drug classes as the disease returns or becomes resistant. By the time someone has received four or more lines of therapy, treatment options narrow and the ability to generate another deep response becomes increasingly valuable.

Elrexfio’s approval therefore represents both a new option and a test of an emerging treatment strategy. A 57.7% response rate in a heavily pretreated population is clinically notable, but the boxed warnings, REMS requirements and accelerated-approval status make careful patient selection and follow-up essential. The next phase will show whether the response durability and confirmatory evidence justify moving the therapy earlier in the multiple-myeloma sequence.